

Weekly New Drug Approvals

Apr. 22th 2024

Pegulicianine

FDA Approval Date: Apr. 17th, 2024


Brand name: Lumisight

Indication: Breast Cancer

Mechanism: Cathepsin inhibitors/Diagnostic dye

Treatment for: Diagnosis and Investigation

Company: Lumicell



Pegulicianine, an optical imaging agent, produces a fluorescent signal after it gets cleaved by cathepsins and matrix metalloproteases. The levels of these enzymes are higher in and around tumor and tumor-associated cells than normal cells. Lumisight is used with the Lumicell Direct Visualization System (DVS) or another fluorescence imaging device approved for use with pegulicianine in the indicated population.

Development timeline for Pegulicianine

